Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by claritason Jul 22, 2008 8:40am
775 Views
Post# 15315892

RBC target drops to $0.15

RBC target drops to $0.15Analyst believes 'prospects are slim for ISA'

Also states 'we believe it is possible that a small to mid-sized player may be interested in voclosporin although we expecxt it to be challenging for a small to mid-sized player to compete from a marketing perspective'.

They expect ISA to minimize the burn rate as much as possible to conserve cash.  RBC extimates that ISA has about $0.15 in cash value as of end of July.  WIth the working capital loan this adds up to $0.27.

The market was right again.  Wonder who had the inside scoop that the results were not good enough.
Bullboard Posts